Patents by Inventor Adam TALBOT

Adam TALBOT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF BETA CATENIN AND USES THEREOF
    Publication number: 20260200909
    Abstract: Provided are compounds of the Formula I: or pharmaceutically acceptable salts thereof, which are useful for the modulation of beta catenin condensates and in the treatment of a variety of conditions or diseases associated therewith.
    Type: Application
    Filed: March 11, 2026
    Publication date: July 16, 2026
    Inventors: Adam Talbot, Thomas Durand-Reville
  • MODULATORS OF BETA CATENIN AND USES THEREOF
    Publication number: 20260138977
    Abstract: Provided are compounds of the Formula I: or pharmaceutically acceptable salts thereof, which are useful for the modulation of beta catenin condensates and in the treatment of a variety of conditions or diseases associated therewith.
    Type: Application
    Filed: November 19, 2025
    Publication date: May 21, 2026
    Inventors: Adam Talbot, Thomas Durand-Reville
  • MODULATORS OF BETA CATENIN AND USES THEREOF
    Publication number: 20260124205
    Abstract: Provided are compounds of the Formula I: or pharmaceutically acceptable salts thereof, which are useful for the modulation of beta catenin condensates and in the treatment of a variety of conditions or diseases associated therewith.
    Type: Application
    Filed: October 21, 2025
    Publication date: May 7, 2026
    Inventors: Adam Talbot, Thomas Durand-Reville
  • Modulators of beta catenin and uses thereof
    Patent number: 12612396
    Abstract: Provided are compounds of the Formula I: or pharmaceutically acceptable salts thereof, which are useful for the modulation of beta catenin condensates and in the treatment of a variety of conditions or diseases associated therewith.
    Type: Grant
    Filed: November 19, 2025
    Date of Patent: April 28, 2026
    Assignee: Dewpoint Therapeutics, Inc.
    Inventors: Adam Talbot, Thomas Durand-Reville
  • Inhibiting USP19
    Patent number: 12590078
    Abstract: The present disclosure is directed to compounds of formulas (I)-(VI), which are useful as modulators of USP19. The compounds are further useful in the inhibition of USP19 and the treatment of diseases or disorders associated with the inhibition of USP19. For instance, the disclosure is concerned with compounds and compositions for inhibition of USP19 and methods of treating diseases associated with the inhibition of USP19 (e.g., Parkinson's disease, Ewing sarcoma, and other metabolic diseases including muscle wasting and diabetes).
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 31, 2026
    Assignee: Valo Health, Inc.
    Inventors: Lawrence Marcin, Bingsong Han, Stephanos Ioannidis, Katherine Kayser-Bricker, Cuixian Liu, Adam Talbot
  • INHIBITING USP19
    Publication number: 20220213059
    Abstract: The present disclosure is directed to compounds of formulas (I)-(VI), which are useful as modulators of USP19. The compounds are further useful in the inhibition of USP19 and the treatment of diseases or disorders associated with the inhibition of USP19. For instance, the disclosure is concerned with compounds and compositions for inhibition of USP19 and methods of treating diseases associated with the inhibition of USP19 (e.g., Parkinson's disease, Ewing sarcoma, and other metabolic diseases including muscle wasting and diabetes).
    Type: Application
    Filed: May 6, 2020
    Publication date: July 7, 2022
    Inventors: Lawrence MARCIN, Bingsong HAN, Stephanos IOANNIDIS, Katherine KAYSER-BRICKER, Cuixian LIU, Adam TALBOT